Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
Cécile Denis, director of research at INSERM, shared a post on LinkedIn:
”The result of an almost 10-year journey: a bispecific nanobody bridging von Willebrand factor to albumin in order to prolong the half-life of VWF and increasing its plasma levels. A potential treatment for patients with decreased VWF levels (Type 1 VWD).
We should not forget that Von Willebrand disease remains largely underestimated and therefore untreated, especially in type 1 patients.
Thank you Ivan Peyron, Caterina Casari, Geneviève McCluskey, Stéphanie Roullet, Vincent Licari, Emilie BOCQUET, Claire Auditeau, Melanie Daniel, sophie susen, Olivier Christophe, Peter Lenting, HITh lab Inserm, INSERM, ANR Agence nationale de la recherche.”
Read the full study here.
Title: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC